Simplifying Global Compliance
FDAnews Device Daily Bulletin
Study: Neupro Transdermal System Shows Therapeutic Benefit in RLS
July 29, 2010
UCB on Wednesday announced the results of a six-month, randomized, double-blind, placebo-controlled clinical study … showing that Neupro (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of restless legs syndrome (RLS).
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing